Home » Stocks » TSHA

Taysha Gene Therapies, Inc. (TSHA)

Stock Price: $20.92 USD 0.55 (2.70%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 794.16M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 37.82M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $20.92
Previous Close $20.37
Change ($) 0.55
Change (%) 2.70%
Day's Open 20.66
Day's Range 20.19 - 21.79
Day's Volume 97,839
52-Week Range 18.16 - 33.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

2 days ago - Business Wire

Taysha Gene Therapies Inc (NASDAQ: TSHA) has announced the online publication of new preclinical data for TSHA-102 in Rett syndrome. The data will be included in the May edition of Brain, a peer-reviewe...

3 days ago - Benzinga

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

3 days ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

1 week ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies ...

1 week ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

4 weeks ago - Business Wire

MoSys Inc. (NASDAQ: MOSY) shares are trading higher after the company announced it has expanded its patent portfolio through the purchase of five patents in the area of search and classification algorit...

Other stocks mentioned: MOSY
1 month ago - Benzinga

Taysha Gene Therapies Inc (NASDAQ: TSHA) has unveiled a deal for global rights to the AAV9 gene therapy program, now known as TSHA-120, to treat giant axonal neuropathy (GAN) Under the terms of the agre...

1 month ago - Benzinga

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the trea...

1 month ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

1 month ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies ...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

2 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

3 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tre...

3 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies ...

3 months ago - Business Wire

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GMAB ...
3 months ago - Seeking Alpha

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

3 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

3 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc., (NASDAQ: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monog...

4 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--AllStripes (formerly RDMD), a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced a multiyear collaboration ...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

4 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

5 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

5 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monoge...

6 months ago - Business Wire

DALLAS & SOMERSET, N.J.--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing adeno-associated virus (AAV)-based g...

6 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogen...

6 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogen...

6 months ago - Business Wire

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogen...

7 months ago - Business Wire

About TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treat... [Read more...]

Industry
Biotechnology
IPO Date
Sep 24, 2020
Stock Exchange
NASDAQ
Ticker Symbol
TSHA
Full Company Profile

Analyst Forecasts

According to 5 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price forecast is 47.30, which is an increase of 126.10% from the latest price.

Price Target
$47.30
(126.10% upside)
Analyst Consensus: Strong Buy